Watch on demand on
14th of February 2024
Clinical trial: >Your< UTI Free Sachets
A new clinical study proved our UTI product substantially improves standard drug treatment for UTIs and helps resolve recurrence. Results were presented in a webinar, now available on demand.
Watch this webinar to discover:
"*" indicates required fields
- the study design and methods used
- details on the product design and the market need
- the results of the clinical study







In the newly published study, the addition of >Your< UTI Free Sachets to standard UTI drug treatment resulted in a significantly lower frequency of relapses and a significantly higher quality of life when compared to antibiotic treatment alone.
the trial.
Lower urinary tract infections (UTIs) are among the most common infections in adult women. Aside from the prevalence, repeating infections present an ongoing issue. Frequent relapses are very common and they significantly affect the quality of life of affected women worldwide.
Antibiotics are the treatment of choice for lower UTIs and while they are efficient at clearing the infection, they mostly fail at preventing recurrence. Alternative approaches are urgently required, especially considering the added challenge of growing antibiotic resistance.
The presented clinical trial aimed to evaluate the efficacy and safety of >Your< UTI Free Sachets in women with acute cystitis and their effect on the recurrence of lower UTIs. The study included 98 female patients aged 18-80 years with active acute cystitis, which was confirmed by a positive bacteriological urine test. The participants were randomized into 2 groups. Both groups received standard antibiotic therapy, while the second group additionally received >Your< UTI Free Sachets.
results overview.
- the addition of >Your< UTI Free Sachets to standard antibiotic therapy resulted in over 4 times lower frequency of relapses compared to antibiotic treatment alone
- while the median number of recurrences per person in the control group was 1, the infection did not recur at all in the majority of the study group
- the study group reported a 20% higher improvement in quality of life during the first week of supplementation when compared to the control group
- compliance in the study group was 98%
The details of the clinical trial, along with in-depth results analysis, were presented in a webinar. Watch it on demand to find out more about the product, market, and possible applications of study results. >Your< UTI Free Sachets are already the number 1 UTI supplement in 2 European markets and the new clinical data will only increase the opportunity for brand owners.
This clinical trial was organized and conducted by Petrovax.
explore further.
Case study: >Your< UTI Free Orosticks
We prepared a case study of a successful campaign that helped our client achieve a #1 position in their market.
>Your< UTI Free Orosticks
A market-leading UTI solution in a new, convenient powder form for direct oral use and improved user experience.
Oops! We could not locate your form.
"*" indicates required fields